Re-purposed drive-through vaccination set-up for Mpox, New York Metropolitan Area

BACKGROUND: This report details how one large medical center in the Metropolitan New York area re-purposed a drive-through COVID-19 vaccination structure to handle a surge in Mpox cases in July 2022. Methods/Results: Simultaneous to on-going COVID -19 vaccination and testing, Mpox vaccination was ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Marina, Chaturvedi, Vishnu, Glassman, Rebecca, Chen, Donald S., El-Khoury, Marc, Dundas, Mary, Feola, Nicholas, Thankachen, Varghese, Yezzo, Marie, Tone, Keri, Williams, Justin, Garrick, Renee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663677/
https://www.ncbi.nlm.nih.gov/pubmed/38028364
http://dx.doi.org/10.1016/j.infpip.2023.100316
Descripción
Sumario:BACKGROUND: This report details how one large medical center in the Metropolitan New York area re-purposed a drive-through COVID-19 vaccination structure to handle a surge in Mpox cases in July 2022. Methods/Results: Simultaneous to on-going COVID -19 vaccination and testing, Mpox vaccination was rolled out in the same drive through structure. More than 1,820 Jynneos (Smallpox and Monkeypox Vaccine, Live, Non-replicating) vaccine dosages were delivered subcutaneously and then intradermally to 1,123 individuals through the open window of their vehicles, averaging 8–10 patients an hour. Five vaccine recipients suffered Mpox rash; there was no exposure among healthcare providers. CONCLUSION: Drive-through vaccination is an efficient model to be redeployed for future unexpected vaccine initiatives.

Ejemplares similares